

## **Not putting the cart before the horse: the complex social and ethical terrain of prenatal exome sequencing**

**Felicity Boardman, Ruth Horn**

### **Angaben zur Veröffentlichung / Publication details:**

Boardman, Felicity, and Ruth Horn. 2023. "Not putting the cart before the horse: the complex social and ethical terrain of prenatal exome sequencing." *European Journal of Human Genetics* 31: 134-35.  
<https://doi.org/10.1038/s41431-022-01225-4>.

## COMMENT OPEN



# Not putting the cart before the horse: the complex social and ethical terrain of prenatal exome sequencing

Felicity Boardman <sup>1</sup>✉ and Ruth Horn <sup>2,3</sup>

© The Author(s) 2022

*European Journal of Human Genetics* (2023) 31:134–135; <https://doi.org/10.1038/s41431-022-01225-4>

Prenatal exome sequencing (PES) for the diagnosis of foetuses ‘with a likely monogenic malformation disorder’ has been available through NHS care in the UK since 2020 [1]. Foetuses undergoing PES typically have anomalies that have been identified through sonographic imaging, and in these instances, a molecular diagnosis is sought to inform management of the pregnancy and/or neonatal care. Indeed, across the globe, the benefits of PES when used in addition to chromosomal microarray analysis (CMA), have been widely emphasised. These benefits not only include diagnostic yields, but also the facilitation of informed decision-making regarding pregnancy dis/continuation, early diagnosis, as well as initiation of pre-symptomatic treatment [2, 3]. Despite these important potential benefits, however, the use of genome-wide approaches to prenatal testing also requires careful consideration given the number of ethical issues that have yet to be adequately explored [4].

Daum et al.’s recent paper, makes the case for expanding the use of PES to foetuses where no anomalies have been previously identified—in other words, suggesting that PES could be usefully employed as a first-tier screening test. The authors claim that PES, even in pregnancies without a specific indication, ‘includes all diagnostic yields of CMA and provides additional findings in a considerable fraction of seemingly healthy foetuses’ (p.11). Their argument for the movement of PES out of the realm of targeted diagnostics into that of screening is therefore based, primarily, on diagnostic yields, and a concern that CMA alone may provide ‘false reassurance’.

Their paper reports on PES conducted on 482 ‘structurally normal’ foetuses between 2017 and 2022 in Israel. In order to determine which results to disclose to parents, the team used the American College of Medical Genetics and Genomics (ACMG)’s list of pathogenic, and likely pathogenic variants, as well as the ACMG’s list of secondary findings [5]. These lists were then further syphoned down by including only those relating to ‘moderate’ or ‘severe’ conditions, as determined by Lazarin et al.’s (2014) taxonomy [6]. Reporting of ‘secondary findings’ were restricted to those with childhood onset, but, importantly, still including susceptibility genes. Using this system, the study identified four foetuses with pathogenic, or likely pathogenic, variants relating to a ‘moderate’ or ‘severe disease’ (all of which were subsequently terminated) and two foetuses with childhood onset secondary findings (both continued to term).

Although the authors emphasise the benefits of this approach in facilitating informed decision-making in pregnancy (in the

absence of pre-conception carrier screening), we believe that there are a number of ethical issues deserving of attention before ES could be seriously considered as a routine form of prenatal screening of ‘structurally normal’ foetuses.

Firstly, the approach used by the authors to determine which variants should be reported back to would-be parents, we believe, requires more thought. Several authors, including Van Rooijk et al. (2020) have argued that the label ‘known pathogenic’ should be applied to genetic variants only very sparingly, given that many that fall into this category do not have a clinical impact in every instance [7]. Whilst van Rooijk et al.’s study was carried out in an older population, the findings may nevertheless be important to consider in the prenatal context where there is limited opportunity to assess the impact of a variant on phenotype. In addition, many variants identifiable through PES (including two found in this study— in SPRED1 and FGFR3) are associated with conditions with wide spectrums of presentation (Legius syndrome and Muenke syndrome respectively), further reducing the ability of PES findings to accurately predict the future clinical impact. Even in instances where pathogenicity, penetrance and expression of a variant are well characterised, the boundaries between ‘mild’, ‘moderate’ and ‘severe’ conditions (which were so pivotal to the authors’ disclosure policy) are not clear cut. In recent years, there has been increasing acknowledgement of the difficulties of relying on taxonomic systems for the classification of condition severity, and of the frequent mismatch between clinical interpretations of life with genetic disease and the perspectives of those who actually live with them [8].

Secondly, and related to the above point, the inherent difficulties with defining terms such as ‘pathogenicity’ and ‘severity’ mean that the likelihood for uncertain or equivocal results being returned through PES is extremely high. This prospect is especially concerning given the potential impact of the results on would-be parents, and their likely influence on decisions around dis/continuation of a pregnancy. Previous research demonstrates the profound psychosocial distress that can follow uncertain prenatal results [9], with cultural, religious and social factors being drawn on to aid interpretation of a future life affected by a (frequently unfamiliar) disability. However, filling the void created by an absence of biomedical certainty with social and cultural interpretations of disability can, in itself, be problematic. Research has demonstrated that poor public knowledge and understanding of both genetic conditions and disability

<sup>1</sup>Warwick Medical School, Gibbet Hill Road, Coventry CV4 7AL, UK. <sup>2</sup>The Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. <sup>3</sup>Ethics in Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany. ✉email: Felicity.Boardman@warwick.ac.uk

Received: 10 October 2022 Accepted: 25 October 2022

Published online: 7 November 2022

can hamper the ability to accurately imagine future lives affected by genetic conditions [10]. Indeed, whilst Daum et al. have emphasised the 'false reassurance' associated with use of CMA without PES, we argue that its inclusion could conversely introduce new uncertainties, decision conflict and distress amongst prospective parents, as has been demonstrated in other prenatal contexts where equivocal results have been identified [11]. In light of this, achieving valid consent for ES, will not only require counselling about the 'limited phenotypic delineation of the foetus' in variants with variable expression and incomplete penetrance (Daum et al., p. 4), but also discussion of the individual meaning of severity and disability for the woman/couple, the (uncertain and variable) meaning of pathogenicity in advanced genomic testing, and findings that go beyond the initially defined list of genetic conditions [12].

Finally, further discussion is needed around how we define 'benefit' in the context of ES in pregnancies without indication. Benefit should not only be evaluated from a clinical perspective, but also from women's perspectives, public health perspectives, and from a health economic perspective. This type of analysis requires in-depth empirical investigation of women's experiences as well as solid economic evaluation to avoid unjustified strain on already overloaded healthcare systems. The latter requires taking account of the costs of data analysis, interpretation and curation as well as of clinical time required to discuss findings with patients [13].

In summary, it is our belief that it is important not to overemphasise the potential benefits of PES and understate some of its inherent uncertainties and potential harms. The uncertainties and limited diagnostic performance of ES should be acknowledged not only in the context of 'mild' to 'moderate' foetal disease, as suggested by the authors (p.10), but also with regard to 'pathogenicity' and 'severe disease'- the definitions of which remain both fraught and contested. It is our view that further social and ethical research is needed to explore the wide range of perspectives (including those of women and disabled people themselves) that can be meaningfully brought to bear on the uncertainties and complexity that currently surround PES results. It is only through such analyses that the wide-ranging social and ethical implications of PES can be fully understood, and before PES could ever be seriously considered as a first-tier screening test.

## REFERENCES

- NHS England, 2021. Rapid exome sequencing service guidance: foetal anomalies testing, <https://www.england.nhs.uk/publication/rapid-exome-sequencing-service-guidance-fetal-anomalies-testing/> (accessed 24/08/22).
- He M, Du L, Xie H, Zhang L, Gu Y, Lei T, et al. 2021. The added value of whole-exome sequencing for anomalous fetuses with detailed prenatal ultrasound and postnatal phenotype. *Front Genet.* <https://doi.org/10.3389/fgene.2021.627204>.
- Guadagnolo D, Mastroromo G, Di Palma F, Pizzuti A, Marchionni E. Prenatal exome sequencing: background, current practice and future perspectives—a systematic review. *Diagnostics.* 2021;1:224.
- Horn R, Parker M. Opening Pandora's box?: ethical issues in prenatal whole genome and exome sequencing. *Prenat Diagnosis.* 2018;38:20–5.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. *Genet Med.* 2015;17:405–24.
- Lazarin G, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic classification of disease severity for evaluation of expanded carrier screening panels. *Plos One.* 2014;9:e114391.
- van Rooij J, Arp P, Broer L, Verlouw J, van Rooij F, Kraaij R, et al. Reduced penetrance of pathogenic ACMG variants in a deeply phenotyped cohort study and evaluation of clinical variant classification over time. *Genet Med.* 2020;22:1812–20.
- Boardman F, Clark C. What is a serious condition? The perspectives of people living with genetic conditions. *Eur J Hum Genet.* 2022;30:160–9.
- Rubel MA, Werner- Lin A, Barg FK, Bernhardt BA. Expert knowledge influences decision-making for couples receiving positive prenatal chromosomal microarray testing results. *Cult Med Psychiatry.* 2017;41:382–406.
- Paul DB. Imagining life with a genetic disorder: the challenge of evaluating health states that exist from birth. *OBM Genet.* 2021;5:11.
- Bredenoord AL, Pennings G, Smeets HJ, de Wert G. Dealing with uncertainties: ethics of prenatal diagnosis and preimplantation genetic diagnosis to prevent mitochondrial disorders. *Hum Reprod Update.* 2008;4:83–94.
- Shkedi-Rafid S, Horton R, Lucassen A. What is the meaning of a 'genomic result' in the context of pregnancy? *Eur J Hum Genet.* 2021;29:225–30.
- Pinxten W, Howard HC. Ethical issues raised by whole genome sequencing. *Best Pract Res Clin Gastroenterol.* 2014;28:269–79.

## AUTHOR CONTRIBUTIONS

FB and RH contributed equally to the writing of this article.

## FUNDING

FB is funded by a Wellcome Trust Investigator Award (2033884/Z/16/Z). RH is funded by the UK Economic and Social Research Council (ES/T00908X/1). She is based at the Wellcome Centre for Ethics and Humanities, which is supported by a Wellcome Centre Grant (203132/Z/16/Z).

## COMPETING INTERESTS

The authors declare no competing interests.

## ADDITIONAL INFORMATION

**Correspondence** and requests for materials should be addressed to Felicity Boardman.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022